Section 573 (21 U.S.C. 301), of the
Minor Use and Minor Species Animal Health Act of 2004 (MUMS Act),
established new regulatory procedures intended to make more
medications legally available to veterinarians and animal owners
for the treatment of minor animal species as well as uncommon
diseases in major animal species. This legislation provides
incentives designed to help pharmaceutical companies overcome the
financial burdens they face in providing liminted - demand animal
drugs. These incentives are only available to sponsors whose drugs
are " MUMS - designated" by the FDA. Participation in the MUMS
program is completely optional for drug sponsors. FDA published a
final rule July 26, 2007 (72 FR 41010),that specifies the criteria
and procedures for requesting MUMS designation as well as the
annual reporting requirements for MUMS designee.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.